Assessment of Tachykinin Receptor 3′ Gene Polymorphism rs3733631 in Rosacea
Table 3
(a) Distribution of genotypes among patients with ET rosacea and healthy controls. (b) Distribution of genotypes among patients with PP rosacea and healthy controls.
(a)
Controls
ET
OR†
95% CI
value
Total
Genotype
C/C
106 (87.7)
65 (97.0)
Ref.
C/G
14 (11.6)
1 (1.5)
0.12
0.02–0.93
0.043
G/G
1 (0.8)
1 (1.5)
1.72
0.11–28.25
0.704
Recessive model
C/C
106 (87.7)
65 (97.0)
Ref.
C/G or G/G
15 (12.4)
2 (3.0)
0.22
0.05–1.01
0.052
Allele contrast
C
226 (93.4)
131 (97.8)
Ref.
G
16 (6.6)
3 (2.2)
0.33
0.10–1.17
0.087
Males
Genotype
C/C
47 (87.0)
23 (92.0)
Ref.
C/G
7 (13.0)
1 (4.0)
0.31
0.04–2.68
0.285
G/G
0 (0.0)
1 (4.0)
—
—
—
Recessive model
C/C
47 (87.0)
23 (92.0)
Ref.
C/G or G/G
7 (13.0)
2 (8.0)
0.62
0.12–3.26
0.57
Allele contrast
C
101 (93.5)
47 (94.0)
Ref.
G
7 (6.5)
3 (6.0)
0.97
0.24–3.95
0.966
Females
Genotype
C/C
59 (88.1)
42 (100.0)
—
C/G
7 (10.4)
0 (0.0)
—
—
—
G/G
1 (1.5)
0 (0.0)
—
—
—
Recessive model
C/C
59 (88.1)
42 (100.0)
—
C/G or G/G
8 (11.9)
0 (0.0)
—
—
—
Allele contrast
C
125 (93.3)
84 (100.0)
—
G
9 (6.7)
0 (0.0)
—
—
—
Note: statistical significance for differences in genotype, G-containing genotype, and allelic frequencies between patients with ET rosacea and healthy controls: (i) = 6.089, df = 2, and = 0.048; = 4.644, df = 1, and = 0.031; = 3.437, df = 1, and = 0.064 among the entire cohort; (ii) = 3.563, df = 2, and = 0.168; = 0.417, df = 1, and = 0.518; = 0.013, df = 1, and = 0.908 among males; (iii) = 5.412, df = 2, and = 0.067; = 5.412, df = 1, and = 0.020; = 5.885, df = 1, and = 0.014 among females. Data are number of subjects and percentage (%); †adjusted for age and gender.
(b)
Controls
PP
OR†
95% CI
value
Total
Genotype
C/C
106 (87.7)
43 (70.5)
Ref.
C/G
14 (11.6)
16 (26.2)
2.81
1.26–6.27
0.011
G/G
1 (0.8)
2 (3.3)
5
0.44–56.98
0.195
Recessive model
C/C
106 (87.7)
43 (70.5)
Ref.
C/G or G/G
15 (12.4)
18 (29.5)
2.96
1.37–6.41
0.006
Allele contrast
C
226 (93.4)
102 (83.6)
Ref.
G
16 (6.6)
20 (16.4)
2.77
1.38–5.57
0.004
Males
Genotype
C/C
47 (87.0)
18 (64.3)
Ref.
C/G
7 (13.0)
8 (28.6)
2.94
0.93–9.32
0.067
G/G
0 (0.0)
2 (7.1)
—
—
—
Recessive model
C/C
47 (87.0)
18 (64.3)
Ref.
C/G or G/G
7 (13.0)
10 (35.7)
3.7
1.22–11.22
0.021
Allele contrast
C
101 (93.5)
44 (78.6)
Ref.
G
7 (6.5)
12 (21.4)
3.9
1.44–10.59
0.008
Females
Genotype
C/C
59 (88.1)
25 (75.8)
Ref.
C/G
7 (10.4)
8 (24.2)
2.7
0.88–8.24
0.082
G/G
1 (1.5)
0 (0.0)
—
—
—
Recessive model
C/C
59 (88.1)
25 (75.8)
Ref.
C/G or G/G
8 (11.9)
8 (24.2)
2.36
0.80–7.01
0.121
Allele contrast
C
125 (93.3)
58 (87.9)
Ref.
G
9 (6.7)
8 (12.1)
1.92
0.70–5.22
0.204
Note: statistical significance for differences in genotype, G-containing genotype, and allelic frequencies between patients with PP rosacea and healthy controls: (i) = 8.217, df = 2, and = 0.016; = 7.999, df = 1, and = 0.005; = 8.709, df = 1, and = 0.003 among the entire cohort; (ii) = 7.517, df = 2, and = 0.023; = 5.808, df = 1, and = 0.016; = 8.044, df = 1, and = 0.005 among males; (iii) = 3.696, df = 2, and = 0.158; = 2.490, df = 1, and = 0.115; = 1.661, df = 1, and = 0.197 among females. Data are number of subjects and percentage (%); †adjusted for age and gender.
